Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M. Forde, Drew M. Pardoll, Stephen Broderick et al.|New England Journal of Medicine|2018Cited by 2.1k
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)Tricia R. Cottrell, Janis M. Taube, Elizabeth D. Thompson et al.|Annals of Oncology|2018Cited by 588
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancersJustina X. Caushi, Kellie N. Smith, Taha Merghoub et al.|Nature|2021Cited by 546
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung CancerValsamo Anagnostou, Victor E. Velculescu, Patrick M. Forde et al.|Cancer Research|2018Cited by 313